All Stories

  1. HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients
  2. Reply: Beyond semantics—Acknowledging diagnostic differences between NAFLD and MASLD
  3. Pre-operative evaluation of spontaneous portosystemic shunts as a predictor of post-hepatectomy liver failure in patients undergoing liver resection for hepatocellular carcinoma
  4. Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST
  5. Dietary Strategies to Modulate Gut Microbiota in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  6. Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab.
  7. 32nd European Congress on Obesity (ECO 2025)
  8. LBP-034-YI Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients
  9. THU-402-YI Real-world practice using liver stiffness measurement through two-dimensional shear wave elastography (SuperSonic Imagine) as a predictive tool for hepatocellular carcinoma risk in noncirrhotic MASLD patients
  10. Tu1604: EXTERNAL VALIDATION OF A PAN-ELASTOGRAPHIC MACHINE LEARNING MODEL FOR NON-INVASIVE DIAGNOSIS OF CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
  11. Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicentr...
  12. Balancing act: LDL-cholesterol control through plant-based vegan and Mediterranean diets
  13. What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?
  14. Generative Artificial Intelligence in Nutrition: A Revolution in Accessibility and Personalization
  15. Suppressing, stimulating and/or inhibiting: The evolving management of HCC patient after liver transplantation
  16. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: is liver fibrosis independent from menopause?
  17. Small bites, big impact: The importance of evening snacks in patients with advanced chronic liver disease
  18. Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis
  19. Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis
  20. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
  21. Malnutrition independently predicts mortality at 18 months in patients hospitalised for severe acute respiratory syndrome corona virus 2 (SARS-coV-2)
  22. New insights on portal hypertension’s screening in people with cystic fibrosis
  23. Porto-sinusoidal vascular disorder in surgical candidates for liver metastases: Prevalence, noninvasive diagnosis, and burden on surgical outcomes
  24. RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives
  25. Sarcopenia evaluated by EASL/AASLD computed tomography-based criteria predicts mortality in patients with cirrhosis: A systematic review and meta-analysis
  26. Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder
  27. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
  28. WED-232-YI Diagnostic accuracy of two-dimensional shear wave elastography (2D-SWE) for non-invasive assessment of liver fibrosis in biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD). Systematic-review and multi-level random...
  29. Evaluation of ChatGPT as a Counselling Tool for Italian-Speaking MASLD Patients: Assessment of Accuracy, Completeness and Comprehensibility
  30. Metformin and the Liver: Unlocking the Full Therapeutic Potential
  31. Reply: AGILE 3+ score, enhancing the diagnostic accuracy of advanced fibrosis in patients with nonalcoholic fatty liver disease
  32. Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
  33. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
  34. The non‐invasive evaluation of liver involvement in patients with cystic fibrosis: A prospective study
  35. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis
  36. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease
  37. Unlocking the Power of Late-Evening Snacks: Practical Ready-to-Prescribe Chart Menu for Patients with Cirrhosis
  38. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
  39. From Listing to Recovery: A Review of Nutritional Status Assessment and Management in Liver Transplant Patients
  40. Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: An exploratory study
  41. A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma
  42. Individual and population screening of varices needing treatment by a simple, safe and accurate test
  43. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis
  44. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
  45. Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients
  46. Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced nonalcoholic fatty liver disease
  47. Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives
  48. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
  49. Letter to the Editor Regarding the Article “Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement” by Zhou and Collaborators
  50. Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies
  51. Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation
  52. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma
  53. Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease
  54. Comparison of screening strategies with two new tests to score and diagnose varices needing treatment
  55. A Combined Baveno VII and Spleen Stiffness Algorithm to Improve the Noninvasive Diagnosis of Clinically Significant Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease
  56. Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm
  57. Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy
  58. Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH)
  59. Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival
  60. Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis
  61. Determinants of weight, psychological status, food contemplation and lifestyle changes in patients with obesity during the COVID-19 lockdown: a nationwide survey using multiple correspondence analysis
  62. Non-invasive diagnosis of clinically significant portal hypertension and treatment with non-selective beta-blockers: a new paradigm
  63. Real-life prevalence of Metabolic Associated Fatty Liver Disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in a tertiary obesity clinic in Italy
  64. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients
  65. Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients
  66. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia
  67. Intestinal failure associated liver disease after weaning off home parenteral nutrition: a 12-month follow up
  68. Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years
  69. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment
  70. Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice
  71. Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges
  72. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
  73. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma
  74. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
  75. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
  76. The role of liver and spleen elastography in advanced chronic liver disease
  77. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
  78. Pattern of macrovascular invasion in hepatocellular carcinoma
  79. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease
  80. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
  81. Liver Measurement Stiffness Can Predict Chemotherapy-related Liver Injury and Complications after Surgery for Liver Metastases
  82. Liver and Spleen Stiffness in Vascular Liver Disease
  83. The changing scenario of hepatocellular carcinoma in Italy: an update
  84. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis
  85. Malnutrition in hospitalized patients with SARS-CoV-2 infection
  86. Transition of patients with chronic intestinal failure from paediatric to adult center
  87. Clinical impact of sarcopenia assessment in patients with liver cirrhosis
  88. Monofocal hepatocellular carcinoma: How much does size matter?
  89. Reply to: “Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma”
  90. Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?
  91. UEG Week 2020 Poster Presentations
  92. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma
  93. Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
  94. Reply to: “Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma”
  95. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes
  96. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study
  97. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments
  98. Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk
  99. Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients
  100. Non-invasive tests for the prediction of primary hepatocellular carcinoma
  101. Non-invasive tests for the prediction of post-hepatectomy liver failure in the elderly
  102. Predictive factors for hepatocellular carcinoma recurrence after curative treatments
  103. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients
  104. Pancreatic ultrasound elastography is not useful to predict the risk of pancreatic fistulas after pancreatic resection
  105. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation
  106. Comparison of prognostic models in predicting survival of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: a multicenter cohort study
  107. Spleen stiffness measurement predicts the development of primary hepatocellular carcinoma better than hepatic venous pressure gradient
  108. Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C
  109. A novel spleen‐dedicated stiffness measurement by FibroScan® improves the screening of high‐risk oesophageal varices
  110. Sound Conclusions: How Splenic Elastography May Decrease the Need for Endoscopic Variceal Surveillance
  111. IDDF2019-ABS-0108 Hepatic decompensation risk is reduced, but not eliminated after direct-acting antivirals: the role of spleen stiffness measurement
  112. Longitudinal evaluation of liver stiffness in three pediatric patients with veno‐occlusive disease
  113. Editorial: collagen proportionate area as a prognostic indicator in NAFLD
  114. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study
  115. Reply to correspondence concerning: “Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection”
  116. Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review
  117. “Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?”
  118. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection
  119. Indocyanine green retention test predict the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients
  120. Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome
  121. Prediction of posthepatectomy liver failure: Role of SSM and LSPS
  122. Ruolo e significato clinico dei metodi non invasivi nella valutazione dell’ipertensione portale nel paziente affetto da epatopatia cronica
  123. Transient Elastography Anticipates the Diagnosis of VOD/SOS after Adult Allogeneic Stem Cell Transplant: Results from a Prospective Study
  124. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients
  125. How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests
  126. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals
  127. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease
  128. Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update
  129. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals
  130. Corrigendum to “Differences in liver stiffness values obtained with new ultrasound elastography machines and fibroscan: A comparative study” [Dig. Liver Dis. 49 (2017) 802–808]
  131. Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals
  132. Pancreatic ultrasound elastography and its clinical use in predicting the risk of pancreatic fistulas after pancreatic resection
  133. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study
  134. A spleen stiffness measurement-based model for recognition of high risk varices: Baveno VI criteria and beyond
  135. Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients
  136. Correction to: Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness
  137. PC.01.2 A SPLEEN STIFFNESS MEASUREMENT-BASED MODEL FOR THE RECOGNITION OF HIGH RISK VARICES: BAVENO VI CRITERIA AND BEYOND
  138. P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C
  139. A spleen stiffness measurement-based model for the recognition of high risk varices: Baveno VI criteria and beyond
  140. IL28 polymorphism and HCC after DAAs for chronic hepatitis C
  141. Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease
  142. Spleen Stiffness by Ultrasound Elastography
  143. Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness
  144. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study
  145. DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods
  146. Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients
  147. Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens
  148. The role of Spleen Stiffness measurement as predictor of HCC recurrence after curative resection in cirrhotic patients
  149. DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods
  150. The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients
  151. Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens
  152. Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients
  153. Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT
  154. Encefalopatia epatica
  155. Gut Microbiota and Celiac Disease